Labcorp Holdings Stock: Analyst Estimates & Ratings

Core Insights - Labcorp Holdings Inc. is a leading global provider of laboratory services with a market capitalization of approximately $21.7 billion [1] Performance Overview - Over the past 52 weeks, Labcorp's stock has increased by 9.9%, underperforming the S&P 500 Index's 10.5% gain, but has outperformed the Health Care Select Sector SPDR Fund's 6% increase [2] - Year-to-date, Labcorp's stock has risen by 14%, compared to the S&P 500's 11.2% increase [2] Business Drivers - The stock's rise in 2025 is attributed to strong performance in the diagnostics business and positive investor sentiment, driven by demand for specialty tests and AI-driven efficiency initiatives [3] Financial Results - In Q3, Labcorp reported an adjusted EPS of $4.18, a 19.4% increase year-over-year, but the stock fell by 5.8% on the earnings announcement day due to a reduction in full-year revenue growth guidance to a range of 7.4% to 8% [4] Analyst Expectations - For the fiscal year ending December 2025, analysts project a 12% year-over-year growth in adjusted EPS to $16.32, with a strong earnings surprise history [5] - The consensus rating among 18 analysts is a "Strong Buy," with 14 "Strong Buy" ratings and four "Holds" [5] Price Target Insights - JP Morgan's analyst has maintained an "Overweight" rating on Labcorp and raised the price target to $317, suggesting a potential upside of 15% from the current levels [6] - The highest price target of $342 implies a possible rally of 30.8% [6]